Clinical Trials Logo
  1. Home
  2. Human Immunodeficiency Virus
  3. NCT02572947

A Pilot Study of MONOtherapy of DOlutegravir in HIV-1 Virologically Suppressed Patients — MONODO  

Human Immunodeficiency Virus Clinical Trial

Official title:
An Interventional, One-arm, Open Label Pilot Study to Assess the Feasibility of Dolutegravir Monotherapy in Virologically Suppressed Patients on Conventional Triple Antiretroviral Therapy of Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors

Clinical Trial Summary

Current HIV treatment guidelines recommend a combination of drugs for the maintenance of antiretroviral therapy (ART). Simplification is considered critical to further scale-up of treatment, to support retention in care and to reduce costs. Dolutegravir is a once daily integrase inhibitor that shows very good tolerability, efficacy, and distinctive resistance profile. The researchers aim at investigating the feasibility of dolutegravir monotherapy in maintenance therapy. Briefly, 10 virologically suppressed patients for at least six months on conventional triple ART of dolutegravir plus two nucleoside reverse transcriptase inhibitors (NRTIs) will be switched to dolutegravir monotherapy for 24 weeks. The primary endpoint is the number of patients completing 24 weeks of dolutegravir monotherapy without experiencing virological failure.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02572947
Study type Interventional
Source University Hospital, Geneva
Contact
Status Completed
Phase Phase 2
Start date June 2016
Completion date September 2017
View Details
See also
  Status Clinical Trial Phase
Terminated NCT03516318 - Using Social Media to Improve ART Retention and Treatment Outcomes Among YLHIV in Nigeria N/A
Completed NCT04653194 - Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat' Phase 3
Completed NCT01792570 - DRV/r + RPV QD: Efficacy and Toxicity Reduction Phase 3
Active, not recruiting NCT04826562 - Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND) Phase 4
Completed NCT04191967 - Thermocoagulation for Treatment of Precancerous Cervical Lesions N/A
Completed NCT02919306 - Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults Phase 1/Phase 2
Completed NCT02812329 - Intervention to Encourage HIV Testing and Counseling Among Adolescents Phase 1
Completed NCT02516930 - A Non-inferiority Randomized Controlled Trial to Evaluate Promoting Condom Use Among MSM and Transgender Individuals in China N/A
Completed NCT02651376 - Safety and Efficacy of Allogenic Adoptive Immune Therapy for Advanced AIDS Patients Phase 1/Phase 2
Recruiting NCT02392884 - HIV Medication Adherence in Underserved Populations N/A
Completed NCT01944371 - Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study Phase 1/Phase 2
Recruiting NCT01778374 - Mater-Bronx Rapid HIV Testing Project. N/A
Completed NCT00914225 - Effect of Bednets and a Water Purification Device on HIV Disease Progression Among ART naïve Patients in Kenya N/A
Completed NCT01460433 - Problems With Immune Recovery in the Gut Tissue N/A
Completed NCT01490346 - Tissue Drug Levels of HIV Medications N/A
Completed NCT01076179 - Kaletra in Combination With Antiretroviral Agents N/A
Completed NCT00317460 - Buprenorphine and Integrated HIV Care Phase 4
Terminated NCT04240210 - Integrase Regimen Switch to Symtuza to Increase Tolerability/Adherence (SYMita) Phase 4
Active, not recruiting NCT04704336 - Integration of Hypertension Management Into HIV Care in Nigeria N/A
Completed NCT03254277 - 3BNC117-LS First-in-Human Phase 1 Study Phase 1